Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke ...

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched “Lunsumio for intravenous infusion 1 mg” and “Lunsumio for intravenous infusion 30 mg” (generic name: mosunetuzumab ...

Chugai Pharmaceutical (TYO: 4519) has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies.